A number of the world’s biggest hearing aid manufacturers have come together to encourage the US health authority to tighten the safety requirements for OTC hearing aids, which will hit the shelves in the US sometime this year.
Novo Nordisk’s diabetes drug, semaglutide, will be sold in the country in a similar price range as its injectable version.
The medtech company will being clinically testing its ostomy add-on product, Heylo, in January.
Miss anything?
Jyske Bank has adjusted its valuation of Genmab’s share price target to DKK 2850 (USD 434.4). Investors should continue to buy, the Danish bank says.
Hearing aid firm Audientes has sent its first shipment of commercially viable hearing aids off to the Indian market, where Audientes has expanded through multiple local partnerships over the past year. Mass production begins now, says CEO Steen Thygesen.
A reorganization of the company’s structure has cost the life of Leo Pharma’s Science & Tech Hub, a five-year-old project in Boston, US.
The Leo Science & Tech Hub, which was the bridgehead for Leo Pharma's efforts in the US, has been shut down, which has meant the man in charge of the operation has left the company.
The European Parliament has adopted regulation that strengthens the EMA's ability to monitor drug and medical equipment shortages in Europe. New EMA groups will be impartial, they say, effectively shutting the door on representatives from the medical industry at large.
The Hearing Industries Association (HIA) has provided the US Food and Drug Administration with a list of recommendations to ensure users of new over-the-counter hearing aids aren't harmed, once the prescriptionless sales channel opens sometime this year.
Hearing group WS Audiology has, on paper, shut down its hearing aid retailer Coselgi – the company has instead been taken under the wing of WSA to simplify legal and accounting purposes, says Jan-Peter Rekling, president of the Nordic region.
Swedish bank Handelsbanken has reduced its share price target for Novo Nordisk by DKK 95 (USD 14.5) due to uncertainties about the pharmaceutical company's forecast for 2022, slated to be publicized on February 2.
Especially Coloplast's continence division is challenged, assesses Danish bank Jyske Bank, which is subsequently lowering its share price target for the medtech company ahead of its Q1 financial report.
A total of 108 patients have been enrolled in Zealand Pharma's crucial trial of glepaglutide as a treatment of short bowel syndrome.
On Wednesday, Leo Pharma has let go of 68 employees, and a total of 1,000 positions in the organization will be affected over the next two years. The new operating model is meant to raise earnings prior to an initial public offering, the company says.
Hearing aid group GN is joining forces with US-based Sonde Health to develop vocal biomarkers to aid in the early detection and management of life-threatening diseases for millions of hearing loss patients.
Demant and GN Hearing lose a little ground as Sonova advances in the US public sales channel for veterans.
Novo Nordisk is teaming up with Swiss start-up Eracal Therapeutics, which is specialized in discovering new drugs from a zebrafish larvae platform. The firms will develop treatments targeted at food intake and other factors associated with obesity.
From April, Russell Thirsk takes up the mantle from Henrik Birk, who has left "to seek new challenges outside Bavarian Nordic."
Several reporting parameters have been adjusted upward by biotech firm Orphazyme, which has fared better than feared in 2021.
Danish power company Ørsted says only positive things about allowing greater insights into the company's global tax payments. In contrast, Coloplast's chair, Lars Rasmussen, says he's had bad experiences with increasing tax transparency.
Administrative entities, universities, and the pharmaceutical industry at large have come together in a new task force, which includes representative from Leo Pharma and Roche Denmark, to secure better terms for Danish clinical research. (Corrected)
French Stallergenes Greer is teaming up with researchers from the Imperial College London to identify biomarkers for a precision medicine approach to allergy immunotherapy.
US-based Verana Health has raised USD 150m from a group of investors, which includes Novo Holdings.
In just four years since the life science incubator was founded, the Bioinnovation Institute's ambitions have only grown. The goal is to double the number of companies under one of the institute's programs, says CEO Jens Nielsen.
QA Manager GMP/GDP Compliance & Audits 
Senior HR Director, HR Denmark, Ferring 
Associate Director, International Medical Affairs 
Director Medical Science 
Senior Associate, CMC Pharmaceutical Development Associate Director, Tax 
GxP QA Compliance Manager for Quality Assurance 
Senior Director, Global Regulatory Lead 
Principal Scientist 
Design Control Specialist / System Engineer Senior Manager, Biostatistics 
QA Specialist Senior Manager, Accounting Operations Medical Director, Translational Medicine 
Senior Key Account Manager Clinical Research Associate 
NORDIC Medical Sales Director 
KLIFO is looking for a Director, Business Support for our Glostrup office Senior Scientist Lead Scientist, Global STA, Royal DSM/Glycom 
Commercial Excellence Lead 
Health Economist 
Chemists are wanted for ALK's internal Aircraft Corps Compound Development Team Lead Associate Director, GMP QA, Biologics/Radiopharmaceuticals 
